W
WAVEMAN · COMPANY
ADIL · Adial Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ADIL

ADIAL PHARMACEUTICALS, INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001513525
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$106.3K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
8
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$106.3K over 180 days
+$106.3K over 90 days · +$106.3K of it by a 10%+ holder
more than 77% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
8 funds added or opened last quarter
below 89% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
8.9% of shares outstanding short · 5.5 days to cover · settled 2026-07-31
more than 72% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -25.1%
-25.1%12M
-86%-54%-22%+11%2025-092025-102025-122026-032026-052026-072026-09 2026-06-29 · Coastlands Capital LP bought $65.0K2026-07-09 · Coastlands Capital LP bought $28.0K2026-07-14 · Coastlands Capital LP bought $5.3K2026-07-10 · Coastlands Capital LP bought $4.6K2026-07-16 · Coastlands Capital LP bought $3.4K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $106.3K bought by insiders over 180 days, 8 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ADIAL PHARMACEUTICALS, INC. insiders bought a net $106.3K of stock across 13 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Coastlands Capital LP
BUY
2026-07-16
1,233.0
$3.4K
Coastlands Capital LP
BUY
2026-07-14
2,000.0
$5.3K
Coastlands Capital LP
BUY
2026-07-10
1,700.0
$4.6K
Coastlands Capital LP
BUY
2026-07-09
10,053.0
$28.0K
Coastlands Capital LP
BUY
2026-06-29
25,000.0
$65.0K
13 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 8 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Stonepine Capital Management, LLC
727,563.0 sh
$1.6M
JANE STREET GROUP, LLC
32,119.0 sh
$82.2K
CITADEL ADVISORS LLC
29,547.0 sh
$75.6K
UBS Group AG
19,147.0 sh
$49.0K
StoneX Group Inc.
19,699.0 sh
$35.7K
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$13.4K POSITION · AS OF 2026-02-28
0.0%
Fidelity Series Total Market Index Fund
$926 POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$646 POSITION · AS OF 2026-03-31
0.0%
Fidelity Total Market Index Fund
$784 POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 3
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-7.8M$-8.3M$-6.9M$-10.9M
NET INCOME$-7,978.0B$-13,197.0B$-5,123.3B$-12.7M
EPS (DILUTED)-11.93-68.01-3.60-12.71
OPERATING CASH FLOW$-6.5M$-6.9M$-6.8M$-11.2M
CASH$5.9M$3.8M$2.8M$4.0M
BUYBACKS$1.7K
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →